January 25, 2021 -- Merck will discontinue development of its COVID-19 vaccine candidates because they produced a lower immune response compared to natural infection or other COVID-19 vaccines.
Merck announced the decision following a review of the findings of a phase I clinical study on its COVID-19 vaccine candidates, V590 and V591. While the vaccines were generally well-tolerated, immune responses were lower than what researchers saw following infection or immunization with another vaccine, the company noted.
As a result of the discontinuation, Merck will record a charge in the fourth quarter of 2020 that will affect the company's results under generally accepted accounting principles (GAAP) results but not its non-GAAP results. Merck and collaborators still plan to submit its V590 and V591 phase I study results for publication in scientific journals.
Despite the change, the company plans to continue to advance clinical programs for its investigational medicines, MK-7110 and MK-4482, the later of which, known as molnupiravir, is being developed in conjunction with Ridgeback Bio. Merck also intends to continue evaluating measles virus vector and vesicular stomatitis virus vector-based platforms.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
